Fate Therapeutics, Inc. (FATE)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Bahram Valamehr M.B.A., Ph.D.
|
President, CEO & Director | 964.7k | -- | 1977 |
|
Mr. Kamal Adawi M.S., MBA
|
CFO & Treasurer | 541.97k | -- | 1979 |
|
Ms. Cindy R. Tahl J.D.
|
Chief Legal & Compliance Officer and Corporate Secretary | 732.7k | -- | 1973 |
|
Ms. Jessica Francis
|
Senior Vice President of Human Resources & Operations | -- | -- | -- |
|
Dr. Martin Hosking
|
Head of Research | -- | -- | -- |
|
Dr. Tunde Babalola Ph.D.
|
Senior Vice President of Technical Operations & Quality | -- | -- | -- |
|
Mr. Ryan Douglas
|
Senior Director of Investor Relations & Business Development | -- | -- | -- |
|
Mr. Andrew Henry
|
Senior Vice President of Clinical Operations | -- | -- | 1964 |
|
Dr. Yu Cai J.D., Ph.D.
|
Head of Intellectual Property & Assistant General Counsel | -- | -- | -- |
Fate Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 161
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Corporate Governance
Upcoming Events
November 12, 2026 at 12:30 PM UTC
Fate Therapeutics, Inc. Earnings Date
